Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary(Churchill Hospital), Andrew J. Pollard(University of Oxford)
Cited by 651
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
|Cell|2021|1.2k
Antibody evasion by the P.1 strain of SARS-CoV-2
|Cell|2021|661